St. Jude Medical Inc. (NYSE:STJ) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $80.91 and last traded at $80.67, with a volume of 652,496 shares changing hands. The stock had previously closed at $80.58.

A number of research analysts have recently issued reports on the company. Zacks Investment Research upgraded St. Jude Medical from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Friday, April 22nd. Piper Jaffray Cos. downgraded St. Jude Medical from an “overweight” rating to a “neutral” rating in a report on Thursday, April 28th. BTIG Research downgraded St. Jude Medical from a “buy” rating to a “neutral” rating in a report on Monday, April 18th. They noted that the move was a valuation call. BMO Capital Markets lifted their price target on St. Jude Medical from $66.00 to $73.00 and gave the company an “outperform” rating in a report on Monday, March 28th. Finally, Cowen and Company upgraded St. Jude Medical from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $66.00 to $73.00 in a report on Monday, March 28th. Twenty investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. St. Jude Medical presently has a consensus rating of “Hold” and an average price target of $73.85.

The stock has a market capitalization of $22.94 billion and a P/E ratio of 32.42. The company has a 50 day moving average of $77.68 and a 200-day moving average of $63.62.

St. Jude Medical (NYSE:STJ) last announced its earnings results on Wednesday, April 20th. The medical technology company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.02. The business had revenue of $1.45 billion for the quarter, compared to analyst estimates of $1.43 billion. St. Jude Medical’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $0.93 EPS. Equities research analysts anticipate that St. Jude Medical Inc. will post $4.06 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Thursday, June 30th will be paid a dividend of $0.31 per share. The ex-dividend date is Tuesday, June 28th. This represents a $1.24 annualized dividend and a dividend yield of 1.54%.

Several large investors have made changes to their positions in STJ. Schroder Investment Management Group increased its stake in shares of St. Jude Medical by 127.2% in the fourth quarter. Schroder Investment Management Group now owns 3,103,759 shares of the medical technology company’s stock valued at $191,720,000 after buying an additional 1,737,451 shares during the period. Boston Partners increased its stake in shares of St. Jude Medical by 32.4% in the fourth quarter. Boston Partners now owns 3,570,791 shares of the medical technology company’s stock valued at $220,568,000 after buying an additional 874,706 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in shares of St. Jude Medical by 484.0% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 505,085 shares of the medical technology company’s stock valued at $31,198,000 after buying an additional 418,602 shares during the period. Vanguard Group Inc. increased its stake in shares of St. Jude Medical by 2.6% in the fourth quarter. Vanguard Group Inc. now owns 16,138,642 shares of the medical technology company’s stock valued at $996,883,000 after buying an additional 411,462 shares during the period. Finally, Winton Capital Group Ltd increased its stake in shares of St. Jude Medical by 790.0% in the fourth quarter. Winton Capital Group Ltd now owns 420,111 shares of the medical technology company’s stock valued at $25,950,000 after buying an additional 372,908 shares during the period.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.